January 26, 2015
RESEARCH TRIANGLE PARK, N.C. — Jeffrey H. Lawson, M.D., Ph.D., Vice Chair for Research, Professor of Surgery and Pathology at Duke University Medical Center (Durham, N.C.), Director of the Vascular Research Laboratory, Director of Clinical Trials for the Department of Surgery and clinical consultant to Humacyte, a pioneering biotechnology firm, is the keynote speaker at the 27th International Symposium on Endovascular Therapy. ISET, held Jan. 31 to Feb. 4 at the Diplomat Hotel in Hollywood, Fla., will bring together thought leaders from around the world for the year’s first and most comprehensive educational symposium showcasing the controversies and advances that keep the endovascular therapy field among the most exciting and innovative in medicine.
Dr. Lawson will present a keynote lecture titled “Bioengineering and the Potential to Create New Blood Vessels” at 8:00 a.m. on Feb. 2. In the keynote, Dr. Lawson will discuss early stage development and clinical testing of Humacyte’s off-the-shelf human bioengineered blood vessel replacement that is being developed for key applications in regenerative medicine and vascular surgery. Dr. Lawson will also present a session titled “Future Procedures in Vascular Therapy” at 5:30 p.m. Feb. 3.
“More than 400,000 hemodialysis patients with end-stage renal disease suffer from yearly surgical procedures having to do with graft complications,” said Dr. Lawson. “Through advances in tissue engineering, we can potentially access non-living, immunologically tolerated blood vessels for implantation that might allow us to reduce number of interventions. This prospective alternative to the current standard of care has the potential to be a significant game-changer for patients.”
Humacyte’s bioengineered blood vessel is cultivated with donated human cells on a tubular scaffold, and then decellularized to allow for allogeneic, off-the-shelf investigational use. Humacyte’s bioengineered blood vessel has performed better than other synthetic and animal-based implants in pre-clinical tests. The product received ‘Fast Track’ designation in 2014 from the Food and Drug Administration for vascular access in patients with End Stage Renal Disease (ESRD) requiring hemodialysis, expediting the regulatory review process. Dr. Lawson collaborated on preclinical and clinical studies, and is a principal investigator for Humacyte’s clinical study in patients with ESRD.
For more information on Humacyte, visit www.humacyte.com.
Humacyte, Inc., a privately held company founded in 2004, is a medical research, discovery and development company with clinical and pre-clinical stage investigational products. Humacyte is primarily focused on developing and commercializing a proprietary novel technology based on human tissue-based products for key applications in regenerative medicine and vascular surgery. The company uses its innovative, proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. These are being developed for potential use in many specific applications, with the goal to significantly improve treatment outcomes for many patients, including those with vascular disease and those requiring hemodialysis. The company’s proprietary technologies are designed to create off-the-shelf products that, once approved, can be utilized in any patient. The company web site is www.humacyte.com.
About the International Symposium on Endovascular Therapy (ISET)
Begun in 1989 and led by acclaimed interventionist Barry Katzen, M.D., ISET is attended annually by physicians, scientists, allied health professionals and industry professionals from around the world. The meeting pioneered the use of live case demonstrations as an educational tool and promotes the multidisciplinary treatment of cardiac and vascular disease by endovascular means. ISET 2015 will take place Jan. 31 to Feb. 4 at the Diplomat Hotel, Hollywood, Fla. For more information, go to http://www.iset.org.